Abstract
The concept of indicated prevention has proliferated in psychiatry, and accumulating evidence suggests that it may indeed be possible to prevent or delay the onset of a first episode of psychosis though adequate interventions in individuals deemed at clinical high risk (CHR) for such an event. One challenge undermining these efforts is the relatively poor predictive accuracy of clinical assessments used in practice for CHR individuals, often leading to diagnostic and therapeutic uncertainty reflected in clinical guidelines promoting a ‘watch and wait’ approach to CHR patients. Using data from published studies, and employing predictive models based on the odds-ratio form of Bayes’ rule, we simulated scenarios where clinical interview, neurocognitive testing, structural magnetic resonance imaging and electrophysiology are part of the initial assessment process of a CHR individual (extended diagnostic approach). Our findings indicate that for most at-risk patients, at least three of these assessments are necessary to arrive at a clinically meaningful differentiation into high- intermediate-, and low-risk groups. In particular, patients with equivocal results in the initial assessments require additional diagnostic testing to produce an accurate risk profile forming part of the comprehensive initial assessment. The findings may inform future research into reliable identification and personalized therapeutic targeting of CHR patients, to prevent transition to full-blown psychosis.
Similar content being viewed by others
References
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168(8):800–805
Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67(2):146–154
Banati R, Hickie IB (2009) Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust 190(4 Suppl):S26–S32
Bodatsch M, Ruhrmann S, Wagner M, Muller R, Schultze-Lutter F, Frommann I, Brinkmeyer J, Gaebel W, Maier W, Klosterkotter J, Brockhaus-Dumke A (2011) Prediction of psychosis by mismatch negativity. Biol Psychiatry 69(10):959–966
Bodatsch M, Klosterkotter J, Muller R, Ruhrmann S (2013) Basic disturbances of information processing in psychosis prediction. Front Psychiatry 4:93
Bousman CA, Yung AR, Pantelis C, Ellis JA, Chavez RA, Nelson B, Lin A, Wood SJ, Amminger GP, Velakoulis D, McGorry PD, Everall IP, Foley DL (2013) Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Transl Psychiatry 3:e251
Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004) Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 70(2–3):315–329
Bramon E, Shaikh M, Broome M, Lappin J, Berge D, Day F, Woolley J, Tabraham P, Madre M, Johns L, Howes O, Valmaggia L, Perez V, Sham P, Murray RM, McGuire P (2008) Abnormal P300 in people with high risk of developing psychosis. NeuroImage 41(2):553–560
Cannon TD (2005) Clinical and genetic high-risk strategies in understanding vulnerability to psychosis. Schizophr Res 79(1):35–44
Carrion RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, Correll CU, Cornblatt BA (2013) Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 70(11):1133–1142
Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, Fillman SG, Rothmond DA, Sinclair D, Tiwari Y, Tsai SY, Weickert TW, Shannon Weickert C (2013) Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci 7:60
Chuma J, Mahadun P (2011) Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. Br J Psychiatry J Ment Sci 199(5):361–366
Clark SR (2009) Decision support for the treatment of community-acquired pneumonia. University of Adelaide, Adelaide
Clark S, Pradhan M, Adams R, Faunt J, Hill A (2003) Workflow Assessment. Paper presented at the HINZ 2003 (2nd: 2003, Darling Harbour, NSW), Brunswick East, Vic., [2003]
Clark S, Pradhan M, Adams R, Faunt J, Hill A, Guterres A (2005) Opportunities to Reduce Delay to Antibiotic in Community Acquired Pneumonia: Early Diagnosis Modelling and Simulation. Paper presented at the National Health Informatics Conference (13th : 2005 : Melbourne, Vic.), Brunswick East, Vic., 2005
Corcoran CM, First MB, Cornblatt B (2010) The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res 120(1–3):16–22
de Koning MB, Bloemen OJ, van Amelsvoort TA, Becker HE, Nieman DH, van der Gaag M, Linszen DH (2009) Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand 119(6):426–442
de Wit S, Schothorst PF, Oranje B, Ziermans TB, Durston S, Kahn RS (2014) Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24:865–873
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 35(3):573–588
Frommann I, Brinkmeyer J, Ruhrmann S, Hack E, Brockhaus-Dumke A, Bechdolf A, Wolwer W, Klosterkotter J, Maier W, Wagner M (2008) Auditory P300 in individuals clinically at risk for psychosis. Int J PsychophysiolOff J Int Organ Psychophysiol 70(3):192–205
Fryers T, Brugha T (2013) Childhood determinants of adult psychiatric disorder. Clin Pract Epidemiol Ment Health CP EMH 9:1–50
Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012a) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69(3):220–229
Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S (2012b) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69(6):562–571
Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, McGuire P (2013a) At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 39(4):923–932
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkotter J, McGuire P, Yung A (2013b) The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70(1):107–120
Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013c) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680–1691
Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH (2014a) Attenuated Psychosis Syndrome: ready for DSM-5.1? Annu Rev Clin Psychol 10:155–192
Fusar-Poli P, Yung AR, McGorry P, van Os J (2014b) Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med 44(1):17–24
Gale C, Glue P, Gallagher S (2013) Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA psychiatry 70(8):880–881
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P (2011) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 16(9):885–886
Jeon YW, Polich J (2003) Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40(5):684–701
Johns LC, van Os J (2001) The continuity of psychotic experiences in the general population. Clin Psychol Rev 21(8):1125–1141
Kaymaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N, Weiser M, Lataster T, van Os J (2012) Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 42(11):2239–2253
Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M (2012) Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(9):1857–1863
Kelleher I, Corcoran P, Keeley H, Wigman JT, Devlin N, Ramsay H, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M (2013) Psychotic symptoms and population risk for suicide attempt: a prospective cohort study. JAMA Psychiatry 70(9):940–948
Klosterkotter J, Ebel H, Schultze-Lutter F, Steinmeyer EM (1996) Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci 246(3):147–154
Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58(2):158–164
Klosterkotter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S (2011) Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry Off J World Psychiatr Assoc 10(3):165–174
Koike S, Takano Y, Iwashiro N, Satomura Y, Suga M, Nagai T, Natsubori T, Tada M, Nishimura Y, Yamasaki S, Takizawa R, Yahata N, Araki T, Yamasue H, Kasai K (2013) A multimodal approach to investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project. Schizophr Res 143(1):116–124
Koutsouleris N, Schmitt GJ, Gaser C, Bottlender R, Scheuerecker J, McGuire P, Burgermeister B, Born C, Reiser M, Moller HJ, Meisenzahl EM (2009) Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. Br J Psychiatry J Ment Sci 195(3):218–226
Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Moller HJ, Riecher-Rossler A (2012) Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull 38(6):1234–1246
Krishnan M, Temel JS, Wright AA, Bernacki R, Selvaggi K, Balboni T (2013) Predicting life expectancy in patients with advanced incurable cancer: a review. J Support Oncol 11(2):68–74
McGee S (2002) Simplifying likelihood ratios. J Gen Intern Med 17(8):646–649
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163(5):790–799
Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T (2006) Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 163(5):800–804
Mihalopoulos C, Harris M, Henry L, Harrigan S, McGorry P (2009) Is early intervention in psychosis cost-effective over the long term? Schizophr Bull 35(5):909–918
Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29(4):703–715
Mossner R, Schuhmacher A, Wagner M, Quednow BB, Frommann I, Kuhn KU, Schwab SG, Rietschel M, Falkai P, Wolwer W, Ruhrmann S, Bechdolf A, Gaebel W, Klosterkotter J, Maier W (2010) DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci 260(3):209–215
Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, Broussard C, Simmons M, Foley DL, Brewer WJ, Francey SM, Amminger GP, Thompson A, McGorry PD, Yung AR (2013) Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry 70(8):793–802
Nieman DH, Koelman JH, Linszen DH, Bour LJ, Dingemans PM, Ongerboer de Visser BW (2002) Clinical and neuropsychological correlates of the P300 in schizophrenia. Schizophr Res 55(1–2):105–113
Owens DK, Nease RF Jr (1997) A normative analytic framework for development of practice guidelines for specific clinical populations. Med Decis Mak Int J Soc Med Decis Mak 17(4):409–426
Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L, McGorry PD (2005) Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31(3):672–696
Pasternak O, Westin CF, Bouix S, Seidman LJ, Goldstein JM, Woo TU, Petryshen TL, Mesholam-Gately RI, McCarley RW, Kikinis R, Shenton ME, Kubicki M (2012) Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J Neurosci Off J Soc Neurosci 32(48):17365–17372
Piras S, Casu G, Casu MA, Orru A, Ruiu S, Pilleri A, Manca G, Marchese G (2014) Prediction and prevention of the first psychotic episode: new directions and opportunities. Ther Clin Risk Manag 10:241–253
Rapoport JL, Giedd JN, Gogtay N (2012) Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 17(12):1228–1238
Riecher-Rossler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, Pfluger M, Radu W, Schindler C, Stieglitz RD (2007) The Basel early-detection-of-psychosis (FEPSY)-study–design and preliminary results. Acta Psychiatr Scand 115(2):114–125
Riecher-Rossler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, Stieglitz RD (2009) Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 66(11):1023–1030
Ruhrmann S, Schultz-Lutter F, Klosterkötter J (2010a) Sub-threshold states of psychosis—a challenge to diagnosis and treatment. Clinical Neuropsychiatry 7(2):72–87
Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkotter J (2010b) Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci 260(Suppl 2):S90–S94
Ruhrmann S, Klosterkotter J, Bodatsch M, Nikolaides A, Julkowski D, Hilboll D, Schultz-Lutter F (2012) Chances and risks of predicting psychosis. Eur Arch Psychiatry Clin Neurosci 262(Suppl 2):S85–S90
Salokangas RK, Ruhrmann S, von Reventlow HG, Heinimaa M, Svirskis T, From T, Luutonen S, Juckel G, Linszen D, Dingemans P, Birchwood M, Patterson P, Schultze-Lutter F, Klosterkotter J, Group E (2012) Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res 138(2–3):192–197
Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD (2012) Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull 38(6):1225–1233
Schultze-Lutter F, Klosterkotter J, Picker H, Steinmeyer EM, Ruhrmann S (2007) Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry 4(1):11–22
Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C (2013) ‘A rose is a rose is a rose’, but at-risk criteria differ. Psychopathology 46(2):75–87
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L (2011) Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 132(1):8–17
Simon AE, Borgwardt S, Riecher-Rossler A, Velthorst E, de Haan L, Fusar-Poli P (2013) Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res 209(3):266–272
Singh S, Kumar A, Agarwal S, Phadke SR, Jaiswal Y (2014) Genetic insight of schizophrenia: past and future perspectives. Gene 535(2):97–100
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rossler A, Borgwardt SJ (2010) Neuroimaging predictors of transition to psychosis–a systematic review and meta-analysis. Neurosci Biobehav Rev 34(8):1207–1222
Sox HC, Blatt MA, Higgins MC, Marton KI (2013) Medical Decision Making, 2nd edn. Wiley, West Sussex
Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:f185
Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H, Altman DG (2013) Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 10(2):e1001381
Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J (2014) Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 41:23–32
Strobl EV, Eack SM, Swaminathan V, Visweswaran S (2012) Predicting the risk of psychosis onset: advances and prospects. Early Interv Psychiatry 6(4):368–379
Thompson A, Nelson B, Bruxner A, O’Connor K, Mossaheb N, Simmons MB, Yung A (2013) Does specific psychopathology predict development of psychosis in ultra high-risk (UHR) patients? Aust NZ J Psychiatry 47(4):380–390
Valmaggia LR, McCrone P, Knapp M, Woolley JB, Broome MR, Tabraham P, Johns LC, Prescott C, Bramon E, Lappin J, Power P, McGuire PK (2009) Economic impact of early intervention in people at high risk of psychosis. Psychol Med 39(10):1617–1626
van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149(1–3):56–62
van der Stelt O, Lieberman JA, Belger A (2005) Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophr Res 77(2–3):309–320
van Tricht MJ, Nieman DH, Koelman JH, van der Meer JN, Bour LJ, de Haan L, Linszen DH (2010) Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry 68(7):642–648
Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR (2013) Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry. doi:10.1111/eip.12105
Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM (2014) Research Review: polygenic methods and their application to psychiatric traits. J Child Psychol Psychiatry 55(10):1068–1087
Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM (2010) Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res 120(1–3):42–48
Yokota F, Thompson KM (2004) Value of information literature analysis: a review of applications in health risk management. Med Decis Mak Int J Soc Med Decis Mak 24(3):287–298
Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J (2005) Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust NZ J Psychiatry 39(11–12):964–971
Yung AR, Killackey E, Hetrick SE, Parker AG, Schultze-Lutter F, Klosterkoetter J, Purcell R, McGorry PD (2007) The prevention of schizophrenia. Int Rev Psychiatry 19(6):633–646
Author information
Authors and Affiliations
Corresponding author
Additional information
Scott Richard Clark and Klaus Oliver Schubert contributed equally to this work and should therefore both be considered first authors.
Rights and permissions
About this article
Cite this article
Clark, S.R., Schubert, K.O. & Baune, B.T. Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. J Neural Transm 122, 155–169 (2015). https://doi.org/10.1007/s00702-014-1325-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1325-9